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Abstract
Spinal muscular atrophy (SMA), a prominent genetic disease of infant mortality, is caused by low 
levels of survival motor neuron (SMN) protein owing to deletions or mutations of the SMN1 gene. 
SMN2, a nearly identical copy of SMN1 present in humans, cannot compensate for the loss of 
SMN1 due to predominant skipping of exon 7 during pre-mRNA splicing. With the recent FDA 
approval of nusinersen (Spinraza™), the potential for correction of SMN2 exon 7 splicing as a 
SMA therapy has been affirmed. Nusinersen is an antisense oligonucleotide that targets intronic 
splicing silencer N1 (ISS-N1) discovered in 2004 at the University of Massachusetts Medical 
School. ISS-N1 has emerged as the model target for testing the therapeutic efficacy of antisense 
oligonucleotides using different chemistries as well as different mouse models of SMA. Here we 
provide a historical account of events that led to the discovery of ISS-N1 and describe the impact 
of independent validations that raised the profile of ISS-N1 as one of the most potent antisense 
targets for the treatment of a genetic disease. Recent approval of nusinersen provides a much-
needed boost for antisense technology that is just beginning to realize its potential. Beyond 
treating SMA, the ISS-N1 target offers myriad potentials for perfecting various aspects of the 
nucleic-acid-based technology for the amelioration of the countless number of pathological 
conditions.
Introduction
Spinal muscular atrophy (SMA) is a prominent and devastating genetic cause of infant 
mortality with an incidence of ~1 in 10,000 live births.1,2 SMA results from low levels of 
survival motor neuron (SMN) protein due to deletions of or mutations in the SMN1 gene.3,4 
SMN is an essential protein involved in diverse functions including snRNP assembly, 
snoRNP assembly, DNA repair, transcription, telomerase biogenesis, translation, RNA 
trafficking, selenoprotein synthesis, stress granule formation and cell signaling.5 While 
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motor neurons and neuromuscular junctions are the first to be affected in SMA,6 other 
tissues including the cardiovascular system, lung, bone, intestine, liver, pancreas, spleen and 
testis are also impacted by low levels of SMN.7–18 The disease spectrum of SMA, divided 
into four types (I through IV) is broad and ranges from infant mortality to adult onset.1 In 
general, SMA severity correlates with SMN2 copy number: the lower the SMN2 copy 
number, the lower the SMN and the more severe the disease.1 Lorson and Hahnen, working 
in the Androphy laboratory at Tufts Medical School, found that SMN2, a nearly identical 
copy of SMN1, fails to compensate for the loss of SMN1 due to defective splicing.19 The 
skipping of SMN2 exon 7 is attributed to a silent c.840C>T transition that corresponds to the 
6th position of the 54-nucleotide (54-nt)-long exon 7.19,20 Since this silent mutation does not 
affect the protein sequence, correction of SMN2 exon 7 splicing has the potential to restore 
the fully functional SMN protein.21,22 The SMN2 exon 7-skipped mRNA itself leads to the 
production of SMNΔ7, a partially stable protein.23–26
Pre-mRNA splicing is a complex process involving multiple RNA-protein, protein-protein 
and RNA-RNA interactions unique for the removal of each individual intron.27 Several cis-
elements and transacting factors have been implicated in regulation of SMN exon 7 splicing. 
Many recent reviews describe the mechanism of splicing regulation of SMN exon 7.28–30 
The generation and nature of various splice variants of SMN have been described 
elsewhere.31–34 Here we provide background information pertaining to the discovery of the 
RNA regulatory element that produced nusinersen (Spinraza™), the first US Food and Drug 
Administration (FDA)-approved drug for SMA.35 Several investigations had demonstrated 
that C6U weakens the 3′-splice site (3′ss) of exon 7 due to its close proximity to the 
3′ss.36–38 However, a subsequent analysis using live cells expressing an exon 7 splicing 
cassette revealed that a weak 5′ss is also a limiting factor for inclusion of exon 7.39 In vivo 
selection is an unbiased approach in which the significance of every nucleotide at each 
exonic position is tested employing a large pool of unique molecules (>1012) with random 
mutations.40,41 Surprisingly, the results of in vivo selection revealed that an adenosine 
residue at the last position (A54) of exon 7 has a more detrimental effect on SMN2 exon 7 
splicing than the natural C6U substitution known to cause SMN2 exon 7 skipping.39 In 
agreement with the results of in vivo selection, an A54G substitution restored exon 7 
inclusion even in the absence of positive cis-elements considered to be important for 
inclusion of exon 7 in both SMN1 and SMN2.39 The strong stimulatory effect of A54G on 
SMN2 exon 7 splicing was attributed to several factors, including the disruption of an 
inhibitory structure that sequesters the 5′ss of exon 7 and/or lengthening of the RNA:RNA 
duplex formed between U1 snRNA and the 5′ss of exon 7.39,40 Both of these mechanisms 
would result in enhanced recruitment of U1 snRNP at the 5′ss of exon 7. Indeed, a follow up 
study confirmed the presence of an inhibitory terminal stem-loop structure (TSL2) that 
facilitates SMN2 exon 7 skipping by sequestering the 5′ss of this exon.42 It was also 
confirmed that increasing the size of the duplex formed between U1 snRNA and the 5′ss of 
exon 7 has a strong stimulatory effect on SMN2 exon 7 inclusion.42
These insights into the processing of the exon 7 SMN2 mRNA brought immediate attention 
to the role of the 5′ss in regulation of SMN exon 7 splicing. Subsequent studies in the Singh 
and Androphy labs at the University of Massachusetts Medical School (UMMS) in 
Worcester, MA, USA discovered Intronic Splicing Silencer N1 (ISS-N1) as the major 
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inhibitory element in SMN exon 7 splicing regulation.35,43,44 Here we describe how the 
discovery of ISS-N1 transformed our understanding of SMN exon 7 splicing regulation and 
paved the way for an antisense-oligonucleotide (ASO)-based therapy for SMA. Nusinersen 
(Spinraza™), the recently FDA-approved drug for SMA, is an ISS-N1 targeting ASO (Figure 
1). We will present what lessons can be learnt from the successes of Spinraza™ for future 
ASO-based therapies of SMA and other diseases.
Defining features of the ISS-N1 target
ISS-N1 is 15-nt long motif located immediately downstream of the 5′ss of exon 7. Deletion 
of ISS-N1 fully restored inclusion of SMN2 exon 7.43 Interestingly, the effect of ISS-N1 
deletion was similar to what was observed with A54G mutation, since positive cis-elements 
became dispensable for exon 7 inclusion when ISS-N1 was deleted.39,43 Hence, Baralle and 
colleagues termed ISS-N1 as the master checkpoint of SMN2 exon 7 splicing.45 Consistent 
with the strong inhibitory effect of ISS-N1, an ASO complementary to and thereby blocking 
ISS-N1 fully restored SMN2 exon 7 inclusion in cultured fibroblasts derived from the SMA 
patient.43 The ASOs employed in this study carried phosphorothioate backbone and the 
2′O-methyl (2′OMe ) modifications in all sugar residues. The stimulatory effect of the ISS-
N1-targeting ASO was robust even at the very low concentration of 5 nM, suggesting that 
the ISS-N1 target is structurally accessible.43 Demonstrating the target specificity, two 
mismatch mutations within the ISS-N1 target as well as in an ASO that targeted it, 
completely abolished the stimulatory effect on splicing of exon 7.43 Additional validation of 
specificity came from an antisense walk in which the effect of three control ASOs that 
annealed to sequences downstream of ISS-N1 were evaluated. As expected, none of these 
control ASOs had any appreciable effect on SMN2 exon 7 splicing.43 These observations 
presented a rare example of a highly specific ASO with desired high activity at a record low 
nanomolar concentration. Equally significant was the target location within an intron, since 
an ASO annealing to an intronic sequence cannot have an adverse effect on mRNA export 
and protein translation. Consistent with the splicing correction, the ISS-N1-targeting ASO 
increased SMN protein in human SMA derived fibroblasts at the low nanomolar 
concentration.43 Overall, these findings were highly instructive in suggesting that the 
devastating consequences of exon 7 skipping could be fully overcome by abrogating the 
activity of an intronic inhibitory element. For commercial exploitation and drug 
development, UMMS filed for intellectual property rights with the US Patent Office in 2004 
and subsequently secured a series of patents on the ISS-N1 target.35,44
At the time the report on the ISS-N1 target was published in 2006, Ionis Pharmaceuticals 
(previously ISIS Pharmaceuticals, Carlsbad, CA, USA), in collaboration with the Krainer 
group (Cold Spring Harbor Laboratory, Long Island, NY, USA), was working to develop an 
ASO-based therapy for SMA. In 2007 Ionis Pharmaceuticals presented the results of 
screening of a large number of ASOs that targeted exon 7.46 The ASOs used in these 
experiments carried phosphorothioate backbone and the 2′-O-methoxyethyl (MOE) 
modifications in all sugar residues. While the findings of this study validated the outcome of 
in vivo selection of exon 7, none of the ASOs identified emerged as a contender for 
therapeutic application. Hoping to find a better lead candidate, Ionis Pharmaceuticals 
continued with another MOE ASO library screen, this time targeting intronic sequences 
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upstream and downstream of exon 7 including the ISS-N1 region.47 This study was 
particularly significant since it allowed a side-by-side comparison of an ISS-N1-targeting 
ASO with a likely novel lead ASO. The ISS-N1-targeting ASO (ASO 10–27) emerged as the 
best ASO in this study.47 Thus, ISS-N1 became the first antisense target for SMA therapy to 
be independently validated by employing an ASO with different chemistry.
Encouraged by these findings, the Krainer laboratory in collaboration with Ionis 
Pharmaceuticals and others, performed a series of in vivo studies with the ISS-N1-targeting 
ASO (ASO 10–27).48–50 The results of these studies showed its unprecedented therapeutic 
efficacy, including the record lifespan extension benefits in the severe SMA models 
(described below). While in vivo studies on the ISS-N1 target were still underway, Ionis 
Pharmaceuticals achieved another milestone in 2010 by securing an exclusive license from 
UMMS to develop SMA drug based on the ISS-N1 target.35 These advances put Ionis 
Pharmaceuticals in 2011 at the forefront of launching a clinical trial of an ISS-N1-targeting 
drug (ISIS-SMNRX) for the treatment of SMA. Subsequent years also witnessed a series of 
in vivo studies employing phosphorodiamidate morpholino oligonucleotides (PMOs) 
targeting ISS-N1.13,15,51–54 These studies provided additional independent validations of the 
efficacy of ISS-N1-targeting ASOs.
Mechanism of Action of ISS-N1-targeting ASOs
The mechanism by which an ISS-N1-targeting ASO stimulates SMN2 exon 7 inclusion 
appears to be complex. Sequences downstream of ISS-N1 harbor TIA1 binding sites.55 
Overexpression of TIA1 restores inclusion of SMN2 exon 7, suggesting that factor(s) 
interacting with ISS-N1 interfere with the recruitment of this protein.55 Owing to the 
presence of two hnRNP A1/A2 motifs spanning the last 14 positions of the 15-nt long ISS-
N1, it has been proposed that the inhibitory effect of ISS-N1 is due to interaction of ISS-N1 
with hnRNP A1/A2.47 ISS-N1 overlaps with an 8-nt long GC-rich sequence (GCRS) 
spanning from the 7th to 14th positions of intron 7.56 Sequestration of GCRS by an 8-mer 
2′OMe ASO also restores SMN2 exon 7 inclusion. The GCRS-targeting ASO partially 
sequestered only one of the two putative hnRNP A1/A2 motifs and yet this ASO produced 
the robust stimulatory effect on SMN2 exon 7 splicing. These surveys suggest that ISS-N1 
may be a composite landing site for several splicing factors.
The most compelling evidence against the role of hnRNP A1/A2 in the negative effect of 
ISS-N1 came from a systematic study employing two 14-mer 2′OMe ASOs called L14 and 
F14.57 F14 and L14 bind to the first and the last fourteen nucleotides of the 15-nt long ISS-
N1, respectively. As expected, F14 restored SMN2 exon 7 inclusion. Surprisingly, L14 
(which sequestered both hnRNP A1/A2 sites but not the 1st position of ISS-N1) strongly 
inhibited SMN2 exon 7 splicing.57 Similar results were observed with two 14-mer ASOs 
with different chemistry, namely locked nucleic acid, suggesting that chemistry is not the 
cause of the L14-induced skipping of SMN2 exon 7.57 These observations ruled out the role 
of hnRNP A1/A2 as the sole regulator(s) associated with the negative effect of ISS-N1 and 
called for a unique mechanism in which sequestration of the first position of ISS-N1 is 
necessary for the stimulatory effect of an ISS-N1 targeting ASO.
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The opposite effect of F14 and L14 on exon 7 splicing was investigated in a recent study 
where the 1st position of ISS-N1 was shown to be involved in the formation of a unique 
long-distance interaction (LDI) with a deep intronic sequence termed ISS-N2 (Figure 2).58 
In particular, an internal stem formed by a LDI (ISTL1) sequesters the 1st position of ISS-
N1 in addition to sequestering a portion of the 5′ss of exon 7.59 An ISS-N1-targeting ASO 
was found to disrupt ISTL1 and increase the accessibility of the 5′ss of exon 7 for the 
recruitment of U1 snRNP.59 Supporting the inhibitory role of ISTL1, an ISS-N2-targeting 
ASO that disrupted ISTL1, also produced a strong stimulatory effect on SMN2 exon 7 
splicing.58 Hence, the stimulatory effect of an ISS-N1-targeting ASO is at least in part due 
to the breaking of the inhibitory structure, ISTL1. It is also likely that the sequestration of 
ISS-N1 promotes recruitment of TIA1 at sequences downstream of ISS-N1.59 In turn, an 
enhanced binding of TIA1 is likely to promote recruitment of U1 snRNP to the 5′ss of exon 
7 causing its inclusion similarly as recently described.59,60 Longer morpholino ASOs that 
target ISS-N1 as well as downstream sequences also stimulated SMN2 exon 7 splicing.52 
These results suggest that the recruitment of TIA1 downstream of ISS-N1 may not be 
critical once the ISS-N1 site is sequestered and ISTL1 is disrupted. However, longer ASOs 
may bring additional changes within the intron 7 structure and these changes may obviate 
the requirement for TIA1 in SMN exon 7 splicing regulation.
In vivo studies with ISS-N1-targeting ASOs
ISS-N1-targeting ASOs have shown remarkable efficacy in ameliorating the phenotype of 
several SMA mouse models when administered soon after birth (Table 1).13,15,48–54,61–72 
Initially, the 2′OMe ISS-N1-targeting ASO43 increased SMN protein in the central nervous 
system (CNS) and improved motor function in the Δ7 mouse.61 This finding led to studies 
from Krainer and colleagues, and independently from the Burghes (The University of Ohio 
School of Medicine, Columbus, OH, USA) and Muntoni groups (University College 
London, London, UK), to further explore the efficacy of the ISS-N1 inhibitor, albeit they 
used contrasting delivery strategies and ASOs of different lengths and chemistries.48,50–53 
The Krainer group first published results using an 18-mer MOE ASO (targeted to intron 7 
nucleotides 10 to 27) in Taiwanese SMA mice, which can be bred to express only the human 
SMN2 transcript.48,50 Remarkably, in these mice subcutaneous (SC) administration of the 
MOE ASO extended median lifespan 25-fold and improved neuromuscular junction 
development.50 This survival benefit remains one of the greatest increases observed for all 
SMA treatments.21 Interestingly, MOE ASO delivery directly to the CNS provided relatively 
little survival benefit.50 Comparatively, the Burghes group observed that a single 27, 54 or 
81 μg intracerebroventricular (ICV) dose of a 20-mer ISS-N1-targeting PMO (targeted to 
intron 7 nucleotides 10 to 29) increased median lifespan nearly 7-fold non-dose dependently 
in the relatively less severe Δ7 mouse model, which is transgenic for human SMN2 plus the 
SMNΔ7 cDNA.51 It remains unclear which ASO chemistry, length and route of delivery 
would provide the most efficacious treatment strategy for SMA. ICV injection is relatively 
invasive, but provides targeted ASO delivery to the CNS. Since the blood brain barrier 
(BBB) in neonatal mice is leaky, ASO delivered systemically could enter the CNS. However, 
BBB leakiness is much less prominent in humans and systemic administration (SC or 
intravascular) would most likely require a high dose to effectively distribute the ASO in the 
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human CNS. High doses could potentially produce toxic effects especially in the liver and 
kidneys. The Krainer laboratory aimed to determine whether SMN restoration in the CNS is 
required to rescue the SMA phenotype in Taiwanese mice.67 SC delivery of an 18-mer ISS-
N1-targeting MOE ASO accompanied with an ICV administration of a decoy MOE ASO 
complementary to the ISS-N1 targeting ASO mitigated the SMA phenotype similarly to SC 
18-mer ISS-N1-targeting MOE ASO administration alone.67 Thus, a SMN increase in 
peripheral organs rather than strictly in the CNS appears important to the therapeutic 
outcome. This finding is not entirely surprising, since a host of recent studies have revealed 
peripheral organ defects in mouse models of SMA.5 Overall, regardless of their chemistry 
and length, ISS-N1-targeting ASOs consistently show the greatest efficacy in improving the 
phenotype of SMA mouse models.21 Collectively, these findings confirm the potency of the 
ISS-N1 target in stimulating SMN2 exon 7 inclusion and for the treatment of SMA. Because 
of this potency, the ISS-N1 target can be useful in investigating and perfecting emerging 
antisense technologies, including chemical modifications that could target the ASO to 
specific organs. For instance, Wood and colleagues have recently reported promising CNS 
delivery of systemically-administered peptide-conjugated PMOs.70,71 However, the 
pharmacokinetics and tolerability of these conjugated ASOs remains to be further examined 
in non-human primates. Nevertheless, these modifications could be particularly informative 
for other genetic diseases in which nucleic-acid-based treatment may be beneficial.
ISS-N1-targeting ASOs also provide a powerful tool to further understand SMA disease 
mechanisms. Using ISS-N1-targeting ASOs allows researchers to examine the temporal 
impact of increasing SMN protein. For example, recent studies show impaired intestine and 
liver development in Taiwanese mice.13,15 SC delivery of a 25-mer PMO targeted to ISS-N1 
normalized the development of these organs indicating that SMN is required for their 
development.12,14 ISS-N1-targeting ASOs can also validate biomarkers that could be 
examined in SMA patients in clinical trials. Namely, electrophysiological abnormalities and 
serum biomarkers in the Δ7 mouse are partially corrected with administration of a 20-mer 
ISS-N1-targeting PMO.63,65,66 Finally, these ISS-N1-targeting ASOs may also develop new 
models of the disease. The Wirth group generated an intermediate SMA mouse model 
through SC administration of suboptimal doses of the 18-mer ISS-N1-targeting MOE ASO 
in severe Taiwanese mice.73 This new model allowed for examination of the benefit of the 
SMA genetic modifier plastin3.73 Intermediate models of the disease would also allow one 
to capture potential defects in organ development that may not be observed in severe models 
with early postnatal lethality.
Therapeutic development
Based on the strong pre-clinical data on the efficacy of ISS-N1, Ionis Pharmaceuticals 
commenced clinical trials with nusinersen, an 18-mer ASO with their proprietary MOE 
chemistry. Given the neuromuscular nature of SMA, nusinersen was delivered intrathecally 
through a lumbar puncture for these clinical trials.74–76 Lumbar puncture effectively 
distributed nusinersen throughout the CNS and did not produce adverse effects beyond what 
had been previously reported for this procedure.75 In the phase I study, nusinersen was well-
tolerated and led to an increase in SMN protein in the cerebrospinal fluid at 9–14 months 
post treatment.74 In addition, the highest dose (9 mg) increased motor function up to 9–14 
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months post treatment as assessed by the Hammersmith Functional Motor Score Expanded 
(HFMSE). The HFSME score increase was particularly promising since it constituted what 
would be considered a clinically meaningful outcome and led to commencement of larger 
phase 2 and 3 clinical trials.74 A phase 2 clinical trial enrolled severe type I SMA infants 
with symptom onset between 3 weeks and 4 months.76 Multiple doses of nusinersen were 
well-tolerated and the majority of the adverse effects were mild. Nusinersen was broadly 
distributed throughout the CNS, increased full-length SMN2 transcript and SMN protein and 
most infants exhibited improved motor function as well as survival and electrophysiological 
function.76 The promising results from these clinical trials led to a placebo-controlled 
double-blinded phase III clinical trials. While the results have yet to be published, the trials 
were terminated early because the primary endpoint at interim analysis was met;77 FDA 
approved Spinraza™ on December 23, 2016. Hence, Spinraza™ became the first FDA-
approved drug for SMA as well as the first antisense drug to treat the major population of a 
genetic disease through splicing correction.
Conclusions and Future directions
Correction of SMN2 exon 7 splicing has long been considered as the most efficacious 
therapeutic option for most SMA patients who retain at least one copy of the SMN2 allele. 
The specificity with which an oligonucleotide corrects splicing remains unmatched. The 
major obstacle in the way of an effective ASO-based therapy of SMA is the delivery of the 
oligonucleotide across the BBB. Other concerns include the stability and the tolerability of 
the oligonucleotide. With the recent FDA approval of Spinraza™, much of the skepticism of 
the oligonucleotide-based therapy of SMA has been put to the rest. Animal studies 
underscore that an early restoration of SMN is key to achieving the maximum therapeutic 
benefit. The availability of Spinraza™ provides SMA patients with their first opportunity to 
receive a drug that could increase SMN levels. This development puts SMA among a 
handful of rare diseases with at least one FDA-approved drug. This is also a great win for 
nucleic-acid therapeutics, which holds the promise for the treatment of rare and orphan 
diseases.
Despite the anticipated enthusiasm among the SMA community and caregivers, it is 
understandable that Spinraza™ may not act with equal efficacy in all SMA patients. This is 
due to a variety of reasons including a limited number of SMN2 alleles, delayed age of drug 
administration and the presence or absence of other disease modifying factors. There may be 
some instances in which Spinraza™ may be completely unusable due to an acute immune 
response. These concerns call for a continued progress towards developing alternative 
therapies for SMA. Fortunately, all oligonucleotide chemistries incorporated into ISS-N1-
targeting ASOs have shown promising results. These independent validations of target 
efficacy suggest bright prospects for developing advanced ASO-based SMA therapies. We 
now know that low levels of SMN affect most tissues. The launch of Spinraza™ has 
invigorated the field of nucleic acid-based therapeutics to further translate the potential use 
of ASOs targeting other regulatory elements in SMN2, and modifications that enable 
penetration into all tissues when delivered employing noninvasive procedures. Recent 
reports have also validated the efficacy of additional antisense targets, including Element 1 
in SMN2 intron 678 and ISS-N2 in SMN2 intron 779 in SMA mouse models. In addition, the 
Singh et al. Page 7
Gene Ther. Author manuscript; available in PMC 2017 September 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
potential for dual-masking ASOs that simultaneously sequester two targets could increase 
the repertoire of ASOs for SMA therapy.80 Given the spectrum of the SMA phenotype, it 
will be useful to have multiple ASO targets so as to treat best treat patients who may not 
respond to specific ASOs.
Success of an ASO-based therapy for SMA has implications for other diseases in which 
nucleic acid-based therapy remains an option. Progress thus far exhibits a classic example of 
smooth transition from fundamental discovery of the ISS-N1 target to independent pre-
clinical validations of ISS-N1-targeting ASOs to independent clinical trials of Spinraza™. 
The coming years will be critical for evaluating the long-term efficacy of Spinraza™ in large 
cohorts comprised of the appropriate age-matched patients. However, there remains a 
concern of drug affordability as the high cost of Spinraza™ might limit the number of 
patients who might otherwise benefit from this drug. Irrespective of these concerns, there is 
every reason to believe that tomorrow’s SMA patients will have more options thanks in part 
to the new insights brought forth from the basic investigations into the regulatory elements 
that control SMN2 exon 7 alternative splicing.
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Figure 1. 
Diagrammatic representation of SMN2 gene and Spinraza mode of action. SMN2 exons are 
represented by colored boxes, while introns are shown as broken lines. Intronic sequence 
immediately down stream of exon 7 is given. ISS-N1 region within this sequence is 
highlighted in pink box. Positions to which Spinraza anneals are indicated. SMN2 pre-
mRNA splicing results in exon 7-included (SMN2FL) and exon 7-skipped (SMN2Δ7) 
transcripts, translation of which leads to production of the full length functional SMN 
protein and a truncated less stable isoform, respectively. Targeting of ISS-N1 by Spriranza 
prevents exon 7 skipping and as a consequence increases levels of the full length SMN.
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Figure 2. 
Mechanism of exon 7 splicing correction by an ISS-N1 targeting ASO. Only relevant 
portions of exon 7 and intron 7 are shown. Exonic and intronic sequences are presented in 
the context of experimentally derived structures.42,58 Neutral and positive numbering start 
from the first position of exon 7 and the first position of intron 7, respectively. Splicing 
regulatory cis-elements and structures, such as the 5′ ss of exon 7, ISS-N1, ISS-N2, TSL2 
and ISTL1 are highlighted. Binding sites for hnRNPA1/A2 and TIA1 are indicated. 
Annealing positions of the ASO and U1 snRNA are shown. Targeting of ISS-N1 by ASO 
causes structural rearrangements, such as disruption of TSL3 and ISTL1 and blocks the 
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binding sites of hnRNP A1/A2. As the result TIA1 binding sites become accessible and the 
recruitment of U1 snRNP to the 5′ ss of exon 7 is increased. Abbreviations: ASO, antisense 
oligonucleotide; ISS, intronic splicing silencer; ISTL, internal stem-loop structure; ss, splice 
site; TSL, terminal stem-loop structure.
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Table 1
In vivo studies using ISS-N1-targeting ASOs
Chemistry (Length) Treatment Details Outcome Measures Ref
Studies in Δ7 mouse model
PS 2′OMe (20) ICV P1, P3, P5, P7, P10 (1 μg) Increased SMN protein in the CNS; improved motor function; 
increased body weight
61
PS MOE (18) ICV P0 (4 μg) Median survival increased 16 d to 26 d; improved muscle and 
NMJ development
49
PS 2OMe (21a) ICV P1, P3, P5 (1 or 10 μg) Median survival increased ~10 d to ~20 d; improved motor 
function
62
PMO (20) ICV P0 (27, 45 or 81 μg) Median survival increased 15 d to ~100 d; improved motor 
function; increased body weight
51
PMO (20, 22 and 25) ICV P0 (0.5, 1, 2, 4 or 6 mM) 25-mer dose-dependently increased median survival 15 d to 
37–126 d
53
PMO (20) ICV P1 (40 μg) Age-dependent normalization of CMAP and MUNE 63
PMO and Dendrimeric 
octoguanadine (Vivo)-
PMO (25)
ICV P0, P3 (2 nM) Median survival increased 17 d to 23 d 64
SC P0, P3 (10, 12 or 24 nM) Median survival increased 17 d to ~27 d
ICV P0 (2, 5, 10 or 12 nM) and SC 
P0, P3 (2, 5, 10 or 12 nM)
Median survival dose-dependently increased 17 d to between 
40–120 d; combination of highest doses improved NMJ 
maturation and motor function
PMO (20) ICV P0–P2, P4 or P6 (40 μg) Treatment at P2 improved CMAP, MUNE and EIM measures 
when examined at P12
65
PMO (20) ICV P1 (40 μg) Normalization of several SMA biomarkers 66
Studies in Taiwanese type I mouse model
PS MOE (18) ICV P1 (20 μg) Median survival increased 10 d to 16 d 50
SC P0–1, P2–3 (40, 50, 80 or 160 
μg/g)
Median survival dose-dependently increased 10 d to between 
84–248 d; improved NMJ maturation, motor function; motor 
neuron protection
ICV P1 (20 μg) and SC P0–1, P2–3 
(50 μg/g)
Median survival increased 10 d to 173 d
PMO (18 and 25) ICV P1 (20 or 40 μg/g) Median lifespan increased 9.5 d to 12 d or 32 d (18-mer) or 43 
d or 85.5 d (25-mer)
52
PMO (25) IV P0 (40 μg/g) Median lifespan increased 9.5 d to >230 d
PMO (25) IV P0 (40 μg/g) and IP or SC P3 (40 
μg/g)
Median survival increased 9.5 d to 93.5 d
Vivo-PMO (25) IV P0 10 μg/g and IP P3 10 μg/g Median survival was 16 d
PMO (25) ICV P0 (10, 20 or 40 μg/g) Median survival increased 9.5 d to 22 d (10 μg/g), 24 d (20 
μg/g) or 212 d (40 μg/g)
54
SC P0 (10, 20 or 40 μg/g) Median survival increased 9.5 d to 22 d (10 μg/g), 58 d (20 
μg/g) or 261 d (40 μg/g); improved NMJ and muscle 
maturation
SC P0 (10 μg/g), SC P5 and every 2 
weeks (10 μg/g)
Survival increased 9.5 d to >150 d; improved muscle and NMJ 
maturation
PS MOE (18) SC P0, P2 (120 mg/kg per day) Median survival increased 10 d to 237 d; improved NMJ 
maturation and motor function; motor neuron protection
67
PS MOE (18) with decoy 
ASO
SC P0, P2 (120 mg/kg per day); ICV 
decoy ASO P0 (10 μg), P20 (20 μg)
Median survival increased 10 d to 212 d; improved NMJ 
maturation and motor function and protected motor neurons
PMO (20) SC P0 (80 μg/g) Mean lifespan increased from 7.7 d to 19.7 d; FDB-2 muscle 
protection
68
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Chemistry (Length) Treatment Details Outcome Measures Ref
PMO (25) SC P0 (40 μg/g) Normalized intestine development 13
PMO (25) SC P0 (40 μg/g) Normalized select miRNA levels in SC, muscle, serum 69
PMO and Pip6a-conjugated 
PMO (20)
IV P0 (10 μg/g) Median survival increased 12 d to 167 d (Pip6a-PMO); no 
effect with unconjugated PMO
70
IV P0, P2 (5 or 10 μg/g each day) Median survival increased 12 d to 57 d (unconjugated) or 283 
d (5 μg/g Pip6a-conjugated) or 457 (10 μg/g Pip6a-
conjugated) days; improved weight gain, NMJ maturation, 
motor function
PMO (25) SC P0 (40 μg/g) Normalized liver development 15
PMO and branched ApoE 
derivative-conjugated (20)
IV P0, P2 (10 mg/kg each day) Median survival increased 10.5 d to 29 (unconjugated) or 78 d 
(ApoE-PMO)
71
Studies in Taiwanese type III mouse model
PS MOE (18) ICV infusion for 7 days in adult mice 
(10, 25, 50, 100 or 150 μg per day)
Increased SMN2 exon 7 inclusion and SMN protein in the 
CNS
48
ICV E15 (2.5, 5, 10 or 20 μg) Dose-dependent increase in tail length and delayed tail 
necrosis
PMO (25) IV P0 (20 μg/g) Tail necrosis onset delayed from 3 to 8 weeks 52
Vivo-PMO (25) IV P0 (10 μg/g) Tail necrosis onset delayed from 3 weeks to 9 months
PS MOE (18) IP P0, P2 (40, 80 or 120 mg/kg) Prevented tail necrosis, but tails significant shorter than 
control mice
67
Study in Burgheron mouse model
PS MOE (20) IP P10, P12 (80 μg/g) Significantly extended lifespan; prevented tail necrosis; 
improved NMJ maturation
72
IP P25,P27 (80 μg/g) Significantly extended lifespan
a
Examined and ISS-N1-targeting ASO as well as ISS-N1-targeting ASO conjugated to sequence to recruit either SF2/ASF or hTra2β1
Abbreviations: 2′OMe, 2′-O-methyl; CMAP, compound muscle action potential; d, days; EIM, electrical impedance myography; ICV, 
intracerebroventricular; IP, intraperitoneal; IV, intravascular; MOE, 2′-O-methoxyethyl; MUNE, motor unit number estimation; NMJ, 
neuromuscular junction; P, postnatal day; PMO, phosphorodiamidate morpholino oligonucleotide; PS, phosphorothioate; SC, subcutaneous
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